MedPath

Latticon Antibody Therapeutics, Inc

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
Drug: LAT010 + ICI
First Posted Date
2024-02-26
Last Posted Date
2025-07-08
Lead Sponsor
Latticon Antibody Therapeutics, Inc
Target Recruit Count
150
Registration Number
NCT06277219
Locations
🇺🇸

D&H Cancer Research Center, Margate, Florida, United States

🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇨🇳

Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.